Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Stephen Harvey Zinner, M.D.

Concepts

This page shows the publications Stephen Zinner has written about Ceftazidime.
Connection Strength

0.229
  1. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med. 1987 12 31; 317(27):1692-8.
    View in: PubMed
    Score: 0.089
  2. Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1985 Jul; 28(1):64-8.
    View in: PubMed
    Score: 0.074
  3. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother. 1995 Feb; 39(2):445-52.
    View in: PubMed
    Score: 0.036
  4. In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods. J Antimicrob Chemother. 1986 Mar; 17 Suppl A:1-5.
    View in: PubMed
    Score: 0.019
  5. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother. 1996 May; 40(5):1108-15.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.